New pill shows promise for rare brain disorders in early trial

NCT ID NCT05758922

Completed Disease control Sponsor: Azafaros B.V. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an oral drug called AZ-3102 in 13 people with GM2 gangliosidosis (Tay-Sachs or Sandhoff disease) or Niemann-Pick type C disease. The main goal was to check safety and how the drug moves through the body over 12 weeks. It was a randomized, double-blind, placebo-controlled trial, meaning neither patients nor doctors knew who got the real drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZ-3102 (oral capsule)
What this could lead to: If successful, this could point toward a treatment option for these rare, progressive neurological diseases.
What could go wrong: This is a very small, early-phase study (13 people) focused on safety and drug levels, not yet on effectiveness. Many drugs fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GM2 GANGLIOSIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

GM2 gangliosidosis Niemann-Pick disease type C Sandhoff disease Tay-Sachs disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GM2 GANGLIOSIDOSIS NIEMANN-PICK DISEASE, TYPE C

Contacts and locations

Locations

Hospital Pequeno Principe

Curitiba, Brazil
Hospital de Clinicas de Porto Alegre

Porto Alegre, Brazil
Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira

Rio de Janeiro, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.